Line 1: |
Line 1: |
− | '''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. | + | '''Table 1 - Clinically significant copy number alterations and regions of loss of heterozygosity in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
| |'''Alteration''' | | |'''Alteration''' |
| |'''Relevant Gene(s)''' | | |'''Relevant Gene(s)''' |
− | |'''CGC Evidence Level''' | + | |'''CGC Evidence Level'''† |
| |'''Subgroup Association(s)''' | | |'''Subgroup Association(s)''' |
| |- | | |- |
Line 71: |
Line 71: |
| |METABRIC IntClust1, ER Positive | | |METABRIC IntClust1, ER Positive |
| |} | | |} |
− | Abbreviations: TNBC, triple negative breast cancer.
| + | † See table below Table 2 for CGC Evidence levels |
| | | |
| + | Abbreviations: TNBC, triple negative breast cancer; LOH, loss of heterozygosity. |
| | | |
− | '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. | + | '''Table 2 - Major clinically significant genes associated with somatic sequence alterations in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
| |'''Gene(s)''' | | |'''Gene(s)''' |
− | |'''CGC Evidence Level''' | + | |'''CGC Evidence Level'''† |
| |'''Clinical Significance and Subgroup Association(s)''' | | |'''Clinical Significance and Subgroup Association(s)''' |
| |'''Therapy Implication(s)''' | | |'''Therapy Implication(s)''' |
Line 234: |
Line 235: |
| Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. | | Abbreviations: BC, breast cancer. TNBC, triple negative breast cancer. |
| | | |
− | '''Cancer Genomics Consortium Levels of Evidence''' | + | †'''Cancer Genomics Consortium Levels of Evidence''' |
| {| class="wikitable" | | {| class="wikitable" |
| |'''Tier''' | | |'''Tier''' |
Line 258: |
Line 259: |
| | | |
| | | |
− | '''Table 3 - Genes with known hereditary risk associations in breast cancer''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. | + | '''Table 3 - Genes with known hereditary risk associations in breast cancer.''' Table derived from Geiersbach et al., 2018 [<nowiki>PMID 32087595</nowiki>] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
| |'''Gene''' | | |'''Gene''' |